Jerry Derevyanny and Julian Lin break down the current state of the cannabis sector (1:00). How companies are massaging their earnings results (3:30). Proper metrics to use as the market develops (7:45). Green Thumb's growth mode and solid margins (16:05). Institutional capital and what will really make the industry soar (21:15). Thoughts on Verano and Goodness Growth (47:25). New states coming online - worthy of excitement? (57:35) NewLake Capital, cannabis REITs and dividend yields (1:08:40).

Show Notes:
How Retail Investors Should Evaluate Cannabis Stocks
What Has Verano So Optimistic About The Cannabis Industry?
MasterClass In Cannabis Investing Redux
My Top Pick: NewLake Capital Yields 12% With Net Cash Balance Sheet And Built-In Growth

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades:  seekingalpha.com/subscriptions

Register for Seeking Alpha's Investing Summit (with your podcast discount code!)

Alex Carchidi talks why he's bullish on the cannabis sector, but not ready to buy stocks (1:15) except for IIPR (2:15). 2 cannabis stocks worth looking at (7:25). Tilray the only international option (13:30). Who looks good in Canada (16:40). Why Alex avoids MSOS ETF (22:30). Legalization, rescheduling and incremental change (23:20).

Show Notes:
Biden administration reportedly moves to reclassify marijuanaTrulieve Cannabis: Up Over 122% In 2024, But Where Does It Go Next?
What Cannabis Reform In Germany Means For North American Marijuana Companies
Canopy Growth Is Climbing, But It Won't Last

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Register for Seeking Alpha's Investing Summit (don't forget your podcast discount code!)

Verano (VRNOF) CEO George Archos and CIO Aaron Miles on recent earnings and why they're the most optimistic they've been (0:45). Company transparency like state by state data (7:50) and what metrics they're each focused on (12:05). Why they're so excited about Florida, Ohio and Pennsylvania (14:35). The federal regulation roller coaster (21:05).

Show Notes:
How Retail Investors Should Evaluate Cannabis Stocks
Cannabis Investors - What You Should Know
Verano Holdings Q1 2024 Earnings Call Transcript
White House mum on where Biden stands with marijuana rescheduling

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Register for Seeking Alpha's Investing Summit (don't forget your podcast discount code!)

Mario Naric, CEO and Founder of Motif Labs, discusses being in the shakeout phase of cannabis in Canada (1:00). Staying private while public companies suffer (5:25). How to grow market share in Canada (12:53). Near-term reality for big Canadian LPs like Tilray and Canopy Growth (18:00). Different products for different markets within US and Canada (23:20). Where should investors allocate their capital in this space? (40:40)

Show Notes:
Oh No, Canada
Cannabis Investing With Alan Brochstein & Julian Lin - REITs And Canadian LPs Over MSOs
DEA to reschedule marijuana as a less dangerous drug: AP

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Motif Labs

David Hart recently became CEO of The Cannabist Company and is focused on building a strong asset base in the US cannabis market (1:35). Metrics and internal expectations, wholesale business; finding ways to improve margin profile and cash generation (11:25). Is more transparency coming?(14:45) Thoughtful ways of approaching debt (17:10). Industry rallies, price drops and technical overhangs (26:40).

Show Notes:
Cresco Labs, Columbia Care call off merger
How Retail Investors Should Evaluate Cannabis Stocks
The Cannabist Company enters into debt repurchase agreement
Seeking Alpha’s Quant Rating on Cannabist

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Bengal Capital's Jerry Derevyanny shares his evolving thoughts on 280E and the process of rescheduling cannabis (2:20). Some uncomfortable truths about how investors should be evaluating cannabis stocks (8:30). When will companies become more transparent? (21:40) Who is handling debt well and who isn't (27:15). Examples of sustainable value creation in the industry (34:00).

Episode transcripts

Show Notes:
Bengal Capital FY2023 Letter
Where Is The Value In Cannabis Stocks?

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Katie Neer and Hirsh Jain break down the dispiriting New York and California cannabis markets (3:00). What the 2 states have gotten wrong, and why it's not being corrected (9:55). Dysfunction and pushing regulators and the law to work better (34:45). Are there investment opportunities in either market? (47:40)

Episode transcripts

Show Notes:
Unpacking New York And California Cannabis Markets
What's The Deal With New York Cannabis?
California Cannabis Market - Deep Dive, Part II

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Cannabis Investing Podcast on Twitter
Katie Neer
Hirsh Jain

Alan Brochstein thinks investors are overly excited about the recent rescheduling announcement, which he says is really no news at all (2:20) Balance sheets, debt, income tax payable and the burden of 280E (4:00) California and New York continuing challenges (23:20) What's right and wrong with Canada (32:30) Broad and specific thoughts on MSOs (38:10).

Subscribe to Alan's 420 Investor

Episode transcripts

Show Notes:
Beaten-Up Planet 13 Is A Solid Cannabis Investment
Trulieve Is Cheap But Perhaps Risky
Curaleaf Is A Bad Cannabis Investment
Why Organigram Is My Favorite Cannabis Stock
Cannabis Investing With Alan Brochstein & Julian Lin - REITs And Canadian LPs Over MSOs

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Cannabis Investing Podcast on Twitter

Alex Carchidi updates us on the psychedelic sector and what critical catalysts are approaching (1:30). Why Compass Pathways, Cybin, and Atai make the most sense for investors at this point (15:00). Pros and cons of 4 main industry stocks, including MindMed (29:50).

Episode transcripts

Show Notes:
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
Psychedelic Stocks: Don't Bet On Just 1 Company
Psychedelic Sunday: Scrutinizing Psychedelic Stocks
Cybin: A Leading Early-Stage Psychedelics Play

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Cannabis Investing Podcast on Twitter

A rundown of reasons to be hopeful and some compelling advice from some of our favorite 2023 conversations. Why Chris DeMuth likes the opportunity in cannabis (1:20) Julian Lin on M&A, debt and disappointment (10:05) Alan Brochstein: waiting for catalysts while working through tough times (12:20) Jesse Redmond discusses the best way to invest in this space (13:35) Emily Paxhia on SG&A containment, gross margins and using the right metrics (17:20).

Episode Transcripts

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Cannabis Investing Podcast on Twitter